AC-Nle-cyclo-(glu-his-D-phe-arg-dap)-trp-NH2 | 1309111-58-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: AC-Nle-cyclo-(glu-his-D-phe-arg-dap)-trp-NH2
• 英文别名: (3S,6S,9R,12S,15S)-15-[[(2S)-2-acetamidohexanoyl]amino]-N-[(2S)-1-amino-3-(1H-indol-3-yl)-1-oxopropan-2-yl]-9-benzyl-6-[3-(diaminomethylideneamino)propyl]-12-(1H-imidazol-5-ylmethyl)-5,8,11,14,18-pentaoxo-1,4,7,10,13-pentazacyclooctadecane-3-carboxamide
• CAS: 1309111-58-7
• 化学式: C₄₈H₆₅N₁₅O₉
• 分子量: 996.1
• InChiKey: KPDWCDURFGPKLY-PDBPWWFNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  72
• 可旋转键数：
  19
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  385
• 氢给体数：
  13
• 氢受体数：
  11

文献信息

• Melanocortin-1 receptor-specific cyclic hexapeptides
  申请人：Palatin Technologies, Inc.

  公开号：US10017539B2

  公开（公告）日：2018-07-10

  Melanocortin receptor-specific cyclic hexapeptides of the formula where R1, R2, R3, R4, R5, R6, R7, R8 and R9 are as defined in the claims, compositions and formulations including the hexapeptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.

  式中的黑色素皮质受体特异性环状六肽 其中 R1、R2、R3、R4、R5、R6、R7、R8 和 R9 如权利要求书中所定义，包括前述式子的六肽或其盐的组合物和制剂，以及预防、改善或治疗黑色素皮质素-1 受体介导或反应性疾病、适应症、条件和综合征的方法。
• Melanocortin receptor-specific peptide with C-terminal naphthylalanine
  申请人：Palatin Technologies, Inc.

  公开号：US10711039B2

  公开（公告）日：2020-07-14

  Melanocortin receptor-specific peptides with a C-terminal naphthylalanine of the formula: where R4, R7, R9, R11, R18, R20, R21a, R21b, R21c and R22 are as defined in the claims, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin receptor-mediated or responsive diseases, indications, conditions and syndromes.

  黑色素皮质素受体特异性肽，其 C 端萘丙氨酸的分子式为 其中R4、R7、R9、R11、R18、R20、R21a、R21b、R21c和R22如权利要求中定义，包括前述式的肽或其盐的组合物和制剂，以及预防、改善或治疗黑色素皮质素受体介导或反应性疾病、适应症、条件和综合征的方法。
• Melanocortin-1 receptor-specific peptides for cytokine storm and inflammation therapy
  申请人：Palatin Technologies, Inc.

  公开号：US11286280B2

  公开（公告）日：2022-03-29

  Methods preventing, ameliorating or treating cytokine storm or inflammatory disease, indications, conditions and syndromes by administration of a therapeutically effective amount of a melanocortin-1 receptor-specific cyclic peptide or pharmaceutically acceptable salt thereof.

  通过施用治疗有效量的黑色素皮质素-1 受体特异性环肽或其药学上可接受的盐来预防、改善或治疗细胞因子风暴或炎症性疾病、适应症、病症和综合征的方法。
• Melanocortin-1 Receptor-Specific Cyclic Peptides
  申请人：PALATIN TECHNOLOGIES, INC.

  公开号：US20130296256A1

  公开（公告）日：2013-11-07

  Melanocortin receptor-specific cyclic peptides of the formula where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined in the specification, compositions and formulations including the peptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.
• Melanocortin-1 Receptor-Specific Cyclic Hexapeptides
  申请人：Palatin Technologies, Inc.

  公开号：US20170008931A1

  公开（公告）日：2017-01-12

  Melanocortin receptor-specific cyclic hexapeptides of the formula where R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 9 are as defined in the claims, compositions and formulations including the hexapeptides of the foregoing formula or salts thereof, and methods of preventing, ameliorating or treating melanocortin-1 receptor-mediated or responsive diseases, indications, conditions and syndromes.